Nurix Therapeutics (Nurix Therapeutics) LT-Debt-to-Total-Asset : 0.07 (As of Feb. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nurix Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Nurix Therapeutics's long-term debt to total assests ratio for the quarter that ended in Feb. 2024 was 0.07.

Nurix Therapeutics's long-term debt to total assets ratio increased from Feb. 2023 (0.01) to Feb. 2024 (0.07). It may suggest that Nurix Therapeutics is progressively becoming more dependent on debt to grow their business.

Nurix Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Nurix Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nurix Therapeutics LT-Debt-to-Total-Asset Chart

Nurix Therapeutics Annual Data

Trend

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.07

Nurix Therapeutics Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.07	0.07

Nurix Therapeutics LT-Debt-to-Total-Asset Calculation

Nurix Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Nov. 2023 is calculated as

LT Debt to Total Assets (A: Nov. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Nov. 2023 )	/	Total Assets (A: Nov. 2023 )
	=	23.125	/	355.598
	=	0.07

Nurix Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2024 is calculated as

LT Debt to Total Assets (Q: Feb. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Feb. 2024 )	/	Total Assets (Q: Feb. 2024 )
	=	21.846	/	312.674
	=	0.07

Nurix Therapeutics (NAS:NRIX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Nurix Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Nurix Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nurix Therapeutics (Nurix Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nurix Therapeutics Inc (NAS:NRIX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1700 Owens Street, Suite 205, San Francisco, CA, USA, 94158

Website

http://www.nurixtx.com

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Executives

Houte Hans Van	officer: Chief Financial Officer	C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Christine Ring	officer: General Counsel	C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Gwenn Hansen	officer: Chief Scientific Officer	C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Stefani Wolff	officer: EVP and COO	C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080
Edward C Saltzman	director	C/O NURIX THERAPEUTICS, 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Paul M Silva	director	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139
Judith A Reinsdorf	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Pierre Beaurang	officer: Chief Business Officer	C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Clay B Siegall	director	21823 30TH DR SE, BOTHELL WA 98021
Ponoi Capital, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Ii Management, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital Ii, Lp	10 percent owner	1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group L P	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129